These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Low-molecular-weight heparin. Wolf H Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267 [TBL] [Abstract][Full Text] [Related]
7. Overview on guidelines and recommendations for generic low-molecular-weight heparins. Harenberg J Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425 [TBL] [Abstract][Full Text] [Related]
8. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients. Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173 [TBL] [Abstract][Full Text] [Related]
11. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128 [TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin: a critical analysis of clinical trials. Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751 [TBL] [Abstract][Full Text] [Related]
13. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143 [TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Crowther M; Hirsh J Semin Thromb Hemost; 1997; 23(1):77-81. PubMed ID: 9156414 [TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Hirsh J; Crowther M Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240 [TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism. Ornstein DL; Hong-Dice YG; Papini JR Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031 [TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of thromboembolism with various low-molecular-weight heparins. Haas S; Blümel G Haemostasis; 1988; 18 Suppl 3():82-7. PubMed ID: 2840379 [TBL] [Abstract][Full Text] [Related]
18. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680 [TBL] [Abstract][Full Text] [Related]
19. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal. Heaton D; Pearce M Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614 [TBL] [Abstract][Full Text] [Related]
20. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. Hirsh J Aust N Z J Med; 1992 Oct; 22(5):487-95. PubMed ID: 1280097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]